{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Stish BJ"],"funding":["NCI NIH HHS"],"pubmed_abstract":["<h4>Purpose</h4>Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer.<h4>Patients and methods</h4>Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["JCO2501486"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12871868"],"repository":["biostudies-literature"],"pubmed_title":["Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer."],"pmcid":["PMC12871868"],"funding_grant_id":["UG1 CA189823","UG1 CA239758","UG1 CA239769","UG1 CA239762","UG1 CA189858"],"pubmed_authors":["Chow S","Diaz Pardo DA","Nauseef JT","Humeniuk MS","Tofthagen C","Adams-Campbell LL","Huang AJ","Stish BJ","Loprinzi CL","Mazza GL","Naha K","Tagawa ST","Novotny PJ","Smith TJ","Chay C","Lustberg MB","Ruddy KJ"],"additional_accession":[]},"is_claimable":false,"name":"Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.","description":"<h4>Purpose</h4>Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer.<h4>Patients and methods</h4>Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T12:08:29.309Z","creation":"2026-07-04T03:11:37.483Z"},"accession":"S-EPMC12871868","cross_references":{"pubmed":["41587370"],"doi":["10.1200/JCO-25-01486","10.1200/jco-25-01486"]}}